Search

Your search keyword '"Svetlana Jezdic"' showing total 18 results
Start Over Author "Svetlana Jezdic"
Sorry, I don't understand your search. ×
18 results on '"Svetlana Jezdic"'

1. Care of adolescents and young adults with cancer in Asia: results of an ESMO/SIOPE/SIOP Asia survey

Author

Chi Kong Li, Rashmi Dalvi, Kan Yonemori, Hany Ariffin, Chuhl Joo Lyu, Mohamad Farid, Julieta Rita N Gonzales-Santos, Qing Zhou, Stefan Bielack, Laurence Brugieres, Anne Blondeel, Samira Essiaf, Fedro Alessandro Peccatori, Svetlana Jezdic, Daniel P Stark, Jean-Yves Douillard, Emmanouil Saloustros, and Giannis Mountzios

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background Adolescents and young adults (AYAs) with cancer require dedicated management encompassing both adult and paediatric cancer services. Following a European survey, the European Society for Medical Oncology, the European Society for Paediatric Oncology and the Asian continental branch of International Society of Paediatric Oncology undertook a similar survey to assess AYA cancer care across Asia.Methods A link to the online survey was sent to healthcare professionals (HCPs) in Asia interested in AYA cancer care. Questions covered the demographics and training of HCPs, their understanding of AYA definition, availability and access to specialised AYA services, the support and advice offered during and after treatment, and factors of treatment non-compliance.Results We received 268 responses from 22 Asian countries. There was a striking variation in the definition of AYA (median lower age 15 years, median higher age 29 years). The majority of the respondents (78%) did not have access to specialised cancer services and 73% were not aware of any research initiatives for AYA. Over two-thirds (69%) had the option to refer their patients for psychological and/or nutritional support and most advised their patients on a healthy lifestyle. Even so, 46% did not ask about smokeless tobacco habits and only half referred smokers to a smoking cessation service. Furthermore, 29% did not promote human papillomavirus vaccination for girls and 17% did not promote hepatitis B virus vaccination for high-risk individuals. In terms of funding, 69% reported governmental insurance coverage, although 65% reported that patients self-paid, at least partially. Almost half (47%) reported treatment non-compliance or abandonment as an issue, attributed to financial and family problems (72%), loss of follow-up (74%) and seeking of alternative treatments (77%).Conclusions Lack of access to and suboptimal delivery of AYA-specialised cancer care services across Asia pose major challenges and require specific interventions.

Published
2019
Full Text
View/download PDF

2. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

Author

Enriqueta Felip, Josep Tabernero, Maria De Santis, Emile Voest, Mark Robson, Fatima Cardoso, Elisabeth G E de Vries, Fedro Alessandro Peccatori, Svetlana Jezdic, Giannis Mountzios, Smita Bhatia, Alexandru Eniu, Luzia Travado, Ulrich Keilholz, Jonas Bergh, Jan Buckner, Friedrich Stiefel, Ahmad Awada, Cristiana Sessa, Olivier Michielin, Marc Ernstoff, Ben Markman, Lisa Licitra, Rossana Berardi, Jill Gilbert, Lidia Schapira, Eva Schernhammer, Jeffrey S Weber, Heinz-Josef Lenz, Piotr Rutkowski, Jennifer Duff, Axel Grothey, Yuichiro Ohe, Saskia Litiere, Hans Wildiers, Christian Dittrich, Michael Kosty, Doug Pyle, Nagi El-Saghir, Jean-Pierre Lotz, Pia Österlund, Nicholas Pavlidis, Gunta Purkalne, Susana Banerjee, Jan Bogaerts, Paolo Casali, Edward Chu, Julia Lee Close, Bertrand Coiffier, Roisin Connolly, Sarah Coupland, Luigi De Petris, Don S Dizon, Linda R Duska, Martin F Fey, Nicolas Girard, Andor W J M Glaudemans, Priya K Gopalan, Stephen M Hahn, Diana Hanna, Christian Herold, Jørn Herrstedt, Krisztian Homicsko, Dennie V Jones, Lorenz Jost, Saad Khan, Alexander Kiss, Claus-Henning Köhne, Rainer Kunstfeld, Stuart Lichtman, Thomas Lion, Lifang Liu, Patrick J Loehrer, Merry Jennifer Markham, Marius Mayerhoefer, Johannes G Meran, Elizabeth Charlotte Moser, Timothy Moynihan, Torsten Nielsen, Kjell Öberg, Antonio Palumbo, Michael Pfeilstöcker, Chandrajit Raut, Scot C Remick, Roberto Salgado, Martin Schlumberger, Hans-Joachim Schmoll, Lowell Schnipper, Charles L Shapiro, Julie Steele, Cora N Sternberg, Florian Strasser, Roger Stupp, Richard Sullivan, Marcel Verheij, Everett Vokes, Jamie Von Roenn, and Yosef Yarden

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) are publishing a new edition of the ESMO/ASCO Global Curriculum (GC) thanks to contribution of 64 ESMO-appointed and 32 ASCO-appointed authors. First published in 2004 and updated in 2010, the GC edition 2016 answers to the need for updated recommendations for the training of physicians in medical oncology by defining the standard to be fulfilled to qualify as medical oncologists. At times of internationalisation of healthcare and increased mobility of patients and physicians, the GC aims to provide state-of-the-art cancer care to all patients wherever they live. Recent progress in the field of cancer research has indeed resulted in diagnostic and therapeutic innovations such as targeted therapies as a standard therapeutic approach or personalised cancer medicine apart from the revival of immunotherapy, requiring specialised training for medical oncology trainees. Thus, several new chapters on technical contents such as molecular pathology, translational research or molecular imaging and on conceptual attitudes towards human principles like genetic counselling or survivorship have been integrated in the GC. The GC edition 2016 consists of 12 sections with 17 subsections, 44 chapters and 35 subchapters, respectively. Besides renewal in its contents, the GC underwent a principal formal change taking into consideration modern didactic principles. It is presented in a template-based format that subcategorises the detailed outcome requirements into learning objectives, awareness, knowledge and skills. Consecutive steps will be those of harmonising and implementing teaching and assessment strategies.

Published
2016
Full Text
View/download PDF

3. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

R, Dummer, A, Hauschild, N, Lindenblatt, G, Pentheroudakis, U, Keilholz, Svetlana, Jezdic, University of Zurich, and Dummer, R

Subjects
Lymphatic metastasis, Pathology, medicine.medical_specialty, Skin Neoplasms, 2720 Hematology, Antineoplastic Agents, 610 Medicine & health, medicine, Humans, Molecular Targeted Therapy, 10266 Clinic for Reconstructive Surgery, Melanoma, Melanoma diagnosis, Neoplasm Staging, Randomized Controlled Trials as Topic, business.industry, General surgery, Follow up studies, 10177 Dermatology Clinic, Hematology, University hospital, Combined Modality Therapy, Clinical Practice, 10022 Division of Surgical Research, Diagnosis treatment, Oncology, Lymphatic Metastasis, Cutaneous melanoma, 2730 Oncology, Immunotherapy, business, Treatment follow up
Abstract

R. Dummer1, A. Hauschild2, N. Lindenblatt3, G. Pentheroudakis4 & U. Keilholz5, on behalf of the ESMO Guidelines Committee* Department of Dermatology, University Hospital Zurich, Zurich, Switzerland; Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany; Division of Plastic and Reconstructive Surgery, University Hospital Zurich, Zurich, Switzerland; Ioannina University Hospital, Ioannina, Greece; Charite Comprehensive Cancer Center, Charite-Universitatsmedizin, Berlin, Germany

Published
2015
Full Text
View/download PDF

4. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

C, Parker, S, Gillessen, A, Heidenreich, A, Horwich, and Svetlana, Jezdic

Subjects
Male, Oncology, medicine.medical_specialty, Randomization, medicine.medical_treatment, Prostate cancer, Prostate, Internal medicine, medicine, Humans, Neoplasm Staging, business.industry, General surgery, Prostatic Neoplasms, Cancer, Hematology, Guideline, medicine.disease, Radiation therapy, Prostate-specific antigen, medicine.anatomical_structure, Docetaxel, business, medicine.drug
Published
2015
Full Text
View/download PDF

5. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

T, Robak, E, Matutes, D, Catovsky, P L, Zinzani, C, Buske, Svetlana, Jezdic, Robak, T, Matutes, E, Catovsky, D, Zinzani, P L, and Buske, C

Subjects
Oncology, Leukemia, Hairy Cell, medicine.medical_specialty, Pathology, business.industry, Hairy cell leukaemia, MEDLINE, Hematology, Guideline, medicine.disease, Leukemia, Moxetumomab pasudotox, Hairy cell leukaemia, guidelines, ESMO, Diagnosis treatment, Internal medicine, medicine, Humans, Hairy cell leukemia, business, Hairy Cell Leukemia Variant
Abstract

No abstract available

Published
2015
Full Text
View/download PDF

7. The ESMO CME program: How practicing oncologists can maintain their knowledge in the E-era? Certification and recertification opportunities

Author

Svetlana Jezdic, Andrés Cervantes, Doris Vola, and Rolf A. Stahel

Subjects
Marketing, Medical education, Service (systems architecture), Strategy and Management, media_common.quotation_subject, education, Medicine (miscellaneous), Certification, Continuing medical education, Excellence, Political science, General partnership, Clinical competence, Pharmacology, Toxicology and Pharmaceutics (miscellaneous), media_common, Accreditation
Abstract

The main objective of the European Society for Medical Oncology (ESMO) continuing medical education (CME) program is to set standards of clinical competence for practice in oncology and encourage the update of knowledge required for professional excellence over a lifetime of service. To guarantee the maintenance levels of knowledge and skills, as well as the improvement in attitudes to cancer care, ESMO has taken several educational initiatives: the ESMO examination; the ESMO medical oncology re-certification program; organisation and/or accreditation of congresses, partnership and joint conferences, supported and labelled courses/meetings. The ESMO flagship journal, Annals of Oncology is an important educational tool that publishes articles addressing multiple oncology disciplines and provides CME points to those who participate in the on-line CME quiz. Currently, ESMO focuses on fostering new challenging CME opportunities such as E-Learning modules and new development tools with an appealing content of ...

Published
2009
Full Text
View/download PDF

8. Peripheral T-cell Lymphomas:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

F, d'Amore, P, Gaulard, L, Trümper, P, Corradini, W-S, Kim, L, Specht, M, Bjerregaard Pedersen, M, Ladetto, and Svetlana, Jezdic

Subjects
Oncology, medicine.medical_specialty, Lymphoma, Ki-1+ Anaplastic Large Cell Lymphoma, Peripheral, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, 030304 developmental biology, Neoplasm Staging, 0303 health sciences, business.industry, General surgery, Medicine (all), Lymphoma, T-Cell, Peripheral, Hematology, University hospital, T-Cell, Prognosis, 3. Good health, Clinical Practice, Transplantation, Diagnosis treatment, 030220 oncology & carcinogenesis, Neoplasm staging, business
Abstract

F. d’Amore1, P. Gaulard2, L. Trumper3, P. Corradini4, W.-S. Kim5, L. Specht6, M. Bjerregaard Pedersen1 & M. Ladetto7, on behalf of the ESMO Guidelines Committee* Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Pathology, Hopital Henri Mondor, Creteil, France; Department of Hematology and Oncology, Georg August University, Gottingen, Germany; Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, Italy; Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Seoul, Korea; Department of Oncology and Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

Published
2015
Full Text
View/download PDF

9. Central venous access in oncology: ESMO Clinical Practice Guidelines

Author

B, Sousa, J, Furlanetto, M, Hutka, P, Gouveia, R, Wuerstlein, J M, Mariz, D, Pinto, F, Cardoso, and Svetlana, Jezdic

Subjects
medicine.medical_specialty, business.industry, Catheter device, Neoplasms therapy, Hematology, University hospital, language.human_language, Venous access, German, Clinical Practice, Oncology, Family medicine, Neoplasms, language, medicine, Central Venous Catheters, Humans, Intensive care medicine, business
Abstract

B. Sousa1, J. Furlanetto2, M. Hutka3, P. Gouveia1, R. Wuerstlein4, J. M. Mariz5, D. Pinto1 & F. Cardoso1, on behalf of the ESMO Guidelines Committee* Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal; German Breast Group, Neu Isenburg, Germany; St George’s University Hospitals, NHS Foundation Trust, London, UK; CCC of LMU, Breast Center, University Hospital Munich, Munich, Germany; Department of Haematology, Instituto Portugues de Oncologia do PortoFrancisco Gentil, Oporto, Portugal

Published
2015

10. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

N, Girard, E, Ruffini, A, Marx, C, Faivre-Finn, S, Peters, and Svetlana, Jezdic

Subjects
Oncology, medicine.medical_specialty, Thymoma, medicine.diagnostic_test, business.industry, Thymus Neoplasm, Biopsy, Hematology, Thymus Neoplasms, medicine.disease, Chemotherapy regimen, Clinical Practice, Text mining, Diagnosis treatment, Internal medicine, medicine, Humans, Neoplasms, Glandular and Epithelial, business, Thymic carcinoma
Published
2015

12. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

A M, Vannucchi, T, Barbui, F, Cervantes, C, Harrison, J-J, Kiladjian, N, Kröger, J, Thiele, C, Buske, and Svetlana, Jezdic

Subjects
Pathology, medicine.medical_specialty, business.industry, Philadelphia Chromosome Negative, Myeloproliferative disease, Hematology, Guideline, University hospital, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Transplantation, Clinical Practice, Oncology, Diagnosis treatment, Family medicine, medicine, Humans, Philadelphia Chromosome, business
Abstract

A. M. Vannucchi1, T. Barbui2, F. Cervantes3, C. Harrison4, J.-J. Kiladjian5, N. Kroger6, J. Thiele7 & C. Buske8 on behalf of the ESMO Guidelines Committee* Department of Experimental and Clinical Medicine, University of Florence, Florence; Hematology and Foundation for Research, Ospedale Papa Giovanni XXIII, Bergamo, Italy; Department of Hematology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain; Department of Haematology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK; Centre d’Investigations Cliniques (INSERM CIC1427), Hopital Saint-Louis and Paris Diderot University, Paris, France; Department of Stem Cell Transplantation, University Hospital Hamburg, Hamburg; University of Cologne, Cologne; Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany

Published
2015

13. Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up

Author

D E, Peterson, C B, Boers-Doets, R J, Bensadoun, J, Herrstedt, and Svetlana, Jezdic

Subjects
Mucositis, medicine.medical_specialty, business.industry, medicine.medical_treatment, General surgery, Mouth Mucosa, Disease Management, Hematology, Guideline, medicine.disease, Chemotherapy regimen, Radiation therapy, Clinical Practice, Gastrointestinal Tract, Diarrhea, Oncology, Diagnosis treatment, Medicine, Humans, medicine.symptom, Disease management (health), business, Intensive care medicine, Stomatitis
Published
2015
Full Text
View/download PDF

14. Prognostic role of epidermal growth factor receptor in localized breast cancer: 15 Years of follow-up

Author

Zora Neskovic-Konstantinovic, Dragica Nikolic-Vukosavljevic, Ksenija Kanjer, Dusica Gavrilovic, Svetlana Jezdic, and Nenad Borojevic

Subjects
Oncology, medicine.medical_specialty, Pathology, receptor, receptors, lcsh:RC254-282, Breast cancer, Epidermal growth factor, Internal medicine, Nodal status, medicine, breast neoplasms, Epidermal growth factor receptor, Autocrine signalling, Receptor, biology, business.industry, steroid, Hematology, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, epidermal growth factor, Tumor progression, biology.protein, prognosis, business, Tamoxifen, hormones, hormone substitutes, and hormone antagonists, medicine.drug
Abstract

Background: The expression of epidermal growth factor receptor (EGF-R) in breast cancer (BC) is generally considered as an unfavorable event during tumor progression. Its predictive role has been fairly well defined: EGF-R expression predicts tamoxifen unresponsiveness. EGF-R role in autocrine growth regulation was confirmed. However, reported results on its prognostic role in BC patients were conflicting. The prognostic role of EGF-R after 15 years of follow-up is analyzed in a group of 70 localized BC patients, presented at diagnosis in clinical stages I-III. Methods: BC patients newly diagnosed from December 1990 until March 1991, treated in accordance to the National Protocol, were selected for EGF-R analysis. Steroid receptors and EGF-R were determined at diagnosis in same frozen tissue samples, using biochemical methods. Except 6 patients who were lost from follow-up in the interval shorter than 60 months, the remaining patients were followed-up from 60-188 months. The total number of events was 32 relapses (46%), and 27 deaths (38.5%). Results: EGF-R expression was found in 28/70 patients (40%), and the EGF-R content higher than 26 fmol - in 15/70 patients (21%). Neither the expression, nor the high content of EGF-R showed any influence on disease-free or overall survival. Levels of EGF-R were similar in relapsing and relapse-free patients. Nodal status had the strongest infuence on prognosis. Conclusion: Our results suggest that the controversial findings, regarding the EGF-R prognostic role, might be the consequence of a genuine weak influence of EGF-R expression on disease outcome. .

Published
2006

15. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

H, Tilly, M, Gomes da Silva, U, Vitolo, A, Jack, M, Meignan, A, Lopez-Guillermo, J, Walewski, M, André, P W, Johnson, M, Pfreundschuh, M, Ladetto, and Svetlana, Jezdic

Subjects
medicine.medical_specialty, Lymphoma, business.industry, Treatment outcome, Hematology, University hospital, Diffuse, Clinical Practice, Neoplasm Recurrence, Diagnosis treatment, Oncology, medicine, Large B-Cell, Humans, Neoplasm staging, Lymphoma, Large B-Cell, Diffuse, Intensive care medicine, business, Humanities
Abstract

H. Tilly1, M. Gomes da Silva2, U. Vitolo3, A. Jack4, M. Meignan5, A. Lopez-Guillermo6, J. Walewski7, M. Andre8, P. W. Johnson9, M. Pfreundschuh10 & M. Ladetto11, on behalf of the ESMO Guidelines Committee* Centre Henri-Becquerel, Universite de Rouen, Rouen, France; Portuguese Institute of Oncology, Lisbon, Portugal; A.O. Citta della Salute e della Scienza di Torino, Turin, Italy; St James’s University Hospital, Leeds, UK; Henri Mondor University Hospital, Creteil, France; Hospital Clinic, Barcelona, Spain; Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland; CHU Dinant-Godinne, UCL Namur, Yvoir, Belgium; Cancer Research UK, University of Southampton, Southampton, UK; Innere Medizin I, Universitat des Saarlandes, Hamburg, Germany; Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

Published
2015

16. Correlation between comorbidity and quality of life in the elderly cancer patients treated with chemotherapy: An ongoing study

Author

I. Popov, Zorica Nikolić-Tomašević, D Radosavljević, and Svetlana Jezdic

Subjects
medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, neoplasms, Cancer, Hematology, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Comorbidity, lcsh:RC254-282, comorbidity, aged, Quality of life (healthcare), Oncology, quality of life, medicine, Physical therapy, Intensive care medicine, business
Published
2002

17. Quality of Life and Neutropenia in Patients with Early Stage Breast Cancer: A Randomized Pilot Study Comparing Additional Treatment with Mistletoe Extract to Chemotherapy Alone

Author

Wilfried Tröger, Svetlana Jezdić, Zdravko Ždrale, Nevena Tišma, Harald J. Hamre, and Miodrag Matijašević

Subjects
mistletoe therapy, breast cancer, randomized clinical trial, quality of life, neutropenia, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: Chemotherapy for breast cancer often deteriorates quality of life, augments fatigue, and induces neutropenia. Mistletoe preparations are frequently used by cancer patients in Central Europe. Physicians have reported better quality of life in breast cancer patients additionally treated with mistletoe preparations during chemotherapy. Mistletoe preparations also have immunostimulant properties and might therefore have protective effects against chemotherapy-induced neutropenia.Patients and Methods: We conducted a prospective randomized open label pilot study with 95 patients randomized into three groups. Two groups received Iscador® M special (IMS) or a different mistletoe preparation, respectively, additionally to chemotherapy with six cycles of cyclophosphamide, adriamycin, and 5-fluoro-uracil (CAF). A control group received CAF with no additional therapy. Here we report the comparison IMS (n = 30) vs. control (n = 31). Quality of life including fatigue was assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30). Neutropenia was defined as neutrophil counts

Published
2009

18. Global Curriculum Edition 2016: European Society for Medical Oncology/American Society of Clinical Oncology Recommendations for Training in Medical Oncology.

Author

Dittrich C, Kosty MP, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir NS, Lotz JP, Österlund P, Pavlidis N, and Purkalne G

Subjects
Curriculum, Europe, Humans, Societies, Medical standards, United States, Clinical Competence, Global Health, Medical Oncology education, Practice Guidelines as Topic
Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results